Cover Image

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study

Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: McLaughlin, Vallerie V. (Author) , Grünig, Ekkehard (Author)
Format: Article (Journal)
Language:English
Published: 28 December 2017
In: BMC pulmonary medicine
Year: 2017, Volume: 17
ISSN:1471-2466
DOI:10.1186/s12890-017-0563-7
Online Access:Verlag, Volltext: http://dx.doi.org/10.1186/s12890-017-0563-7
Verlag, Volltext: https://doi.org/10.1186/s12890-017-0563-7
Get full text
Author Notes:Vallerie V. McLaughlin, Pavel Jansa, Jens E. Nielsen-Kudsk, Michael Halank, Gérald Simonneau, Ekkehard Grünig, Silvia Ulrich, Stephan Rosenkranz, Miguel A. Gómez Sánchez, Tomás Pulido, Joanna Pepke-Zaba, Joan Albert Barberá, Marius M. Hoeper, Jean-Luc Vachiéry, Irene Lang, Francine Carvalho, Christian Meier, Katharina Mueller, Sylvia Nikkho and Andrea M. D’Armini
Description
Summary:Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH.
Item Description:Gesehen am 16.11.2018
Physical Description:Online Resource
ISSN:1471-2466
DOI:10.1186/s12890-017-0563-7

Similar Items